TWI899163B - 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 - Google Patents

使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Info

Publication number
TWI899163B
TWI899163B TW110106714A TW110106714A TWI899163B TW I899163 B TWI899163 B TW I899163B TW 110106714 A TW110106714 A TW 110106714A TW 110106714 A TW110106714 A TW 110106714A TW I899163 B TWI899163 B TW I899163B
Authority
TW
Taiwan
Prior art keywords
subject
finatinib
progression
pharmaceutically acceptable
baseline
Prior art date
Application number
TW110106714A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146022A (zh
Inventor
希德基 加倫
華同 鄧
奧瑞蓮 維亞科茲
卜丁根 漢斯 克里斯丁 凡
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202146022A publication Critical patent/TW202146022A/zh
Application granted granted Critical
Publication of TWI899163B publication Critical patent/TWI899163B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
TW110106714A 2020-02-28 2021-02-25 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 TWI899163B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062982872P 2020-02-28 2020-02-28
US62/982,872 2020-02-28
US202063051756P 2020-07-14 2020-07-14
US63/051,756 2020-07-14

Publications (2)

Publication Number Publication Date
TW202146022A TW202146022A (zh) 2021-12-16
TWI899163B true TWI899163B (zh) 2025-10-01

Family

ID=74885089

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110106714A TWI899163B (zh) 2020-02-28 2021-02-25 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Country Status (13)

Country Link
US (1) US20230091561A1 (https=)
EP (1) EP4110339A1 (https=)
JP (1) JP2023515528A (https=)
KR (1) KR20220148826A (https=)
CN (1) CN115175682A (https=)
AU (1) AU2021227674A1 (https=)
BR (1) BR112022017102A2 (https=)
CA (1) CA3170685A1 (https=)
CL (1) CL2022002317A1 (https=)
IL (1) IL295476A (https=)
MX (1) MX2022010513A (https=)
TW (1) TWI899163B (https=)
WO (1) WO2021173740A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4732904A2 (en) * 2015-10-06 2026-04-29 F. Hoffmann-La Roche AG Method for treating multiple sclerosis
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
MX2021000094A (es) * 2018-07-20 2021-03-25 Merck Patent Gmbh Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.
AU2021249129A1 (en) * 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Aaron Gregson, et al. "Emerging small-molecule treatments for multiple sclerosis: focus on B cells." F1000Res. 8: 2019 Mar 1; F1000 Faculty Rev-245.

Also Published As

Publication number Publication date
CN115175682A (zh) 2022-10-11
KR20220148826A (ko) 2022-11-07
US20230091561A1 (en) 2023-03-23
WO2021173740A1 (en) 2021-09-02
JP2023515528A (ja) 2023-04-13
CL2022002317A1 (es) 2023-03-03
EP4110339A1 (en) 2023-01-04
MX2022010513A (es) 2022-09-21
AU2021227674A1 (en) 2022-07-21
CA3170685A1 (en) 2021-09-02
TW202146022A (zh) 2021-12-16
IL295476A (en) 2022-10-01
BR112022017102A2 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
US12605376B2 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
US20240041894A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP2021181501A (ja) 免疫不全疾患を処置するための方法
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
TW201442709A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）治療漸進形式的多發性硬化症
TW201821080A (zh) 用於治療發炎性疾病之化合物及其醫藥組合物
TW202128175A (zh) 藉由投予（Ｒ）—２—［３—［４—胺基—３（２—氟—４—苯氧基—苯基）吡唑并［３，４—ｄ］嘧啶—１—基］哌啶—１—羰基］—４—甲基—４—［４—（氧呾—３—基）哌—１—基］戊—２—烯腈來治療免疫血小板減少症之方法
KR20220012281A (ko) 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법
KR20240004451A (ko) Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
TW202508596A (zh) 使用腫瘤壞死因子α之小分子抑制劑治療乾癬
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
TW202517276A (zh) 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法
US20190290635A1 (en) Methods of treating brain cancer using agents that alter activity of a metabolic pathway
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
HK40087403A (zh) 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
TW202535404A (zh) 使用ｂｔｋ抑制劑２－［（３ｒ）－３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療與異位性皮炎和／或結節性癢疹相關的搔癢
TW202210068A (zh) 用於治療家族性地中海型發熱病的cxcr-2抑制劑
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法